Okay, here’s a significantly expanded article based on the provided STAT News snippet, aiming for comprehensive coverage, E-E-A-T principles, and the requested components. It’s structured to be Google News-kind and informative. I’ve added ample detail, analysis, and context. I’ve also included the required HTML elements. This is a long response, as requested by the prompt.

“`html

Biotech News & Analysis: Europe’s Pharma Shift, Covid-19 Advances & More

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning.Today, we delve into the notable regulatory changes unfolding in Europe, examine how telehealth is reshaping the pharmaceutical landscape, and provide updates on key clinical trials and executive appointments.

The Need-to-Know This Morning

• Stoke Therapeutics appointed Ian Smith as its permanent CEO. He had been interim CEO since March. This appointment signals stability for the gene therapy company as it progresses its pipeline.
• Invivyd received FDA clearance to initiate two pivotal clinical trials evaluating its antibody treatment, pemivibart, for Covid-19 prevention. The trials are designed to support a potential Biologics License Request (BLA).
• AstraZeneca and Daiichi Sankyo announced that their antibody-drug conjugate (ADC), Datroway (sacituzumab govitecan-hziy), demonstrated statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) in patients with advanced, heavily pre-treated triple-negative breast cancer (TNBC).
• Abivax presented positive 8-week data from a Phase 2b study of obefazimod in ulcerative colitis, showing a statistically significant clinical remission rate.

Europe Nears Sweeping Pharma policy Overhaul

European officials are nearing completion of a landmark overhaul of the E.U.’s pharmaceutical policies – the most significant in decades. This initiative, aimed at balancing improved access to